Clinical Approach in the Management of Paediatric Patients with Familial Hypercholesterolemia: A National Survey Conducted by the LIPIGEN Paediatric Group

Pederiva, Cristina;Gazzotti, Marta;Arca, Marcello;Averna, Maurizio;Banderali, Giuseppe;Biasucci, Giacomo;Brambilla, Marta;Buonuomo, Paola;Calabrò, Paolo;Cipollone, Francesco;Citroni, Nadia;D’Addato, Sergio;Del Ben, Maria;Genovesi, Simonetta;Guardamagna, Ornella;Iannuzzo, Gabriella;Iughetti, Lorenzo;Mandraffino, Giuseppe;Maroni, Lorenzo;Mombelli, Giuliana;Muntoni, Sandro;Nascimbeni, Fabio;Passaro, Angelina;Pellegatta, Fabio;Pirro, Matteo;Pisciotta, Livia;Pujia, Roberta;Sarzani, Riccardo;Scicali, Roberto;Suppressa, Patrizia;Zambon, Sabina;Zenti, Maria;Calandra, Sebastiano;Catapano, Alberico;Tarugi, Patrizia;Galimberti, Federica;Casula, Manuela;Capra, Maria

2023-01-01

---

Abstract

Detection and treatment of patients with familial hypercholesterolemia (FH) starting from childhood is fundamental to reduce morbidity and mortality. The activity of National realities such as the LIPIGEN (LIpid transPort disorders Italian GEnetic Network) Paediatric Group, founded in 2018, is a milestone in this context. The aim of this exploratory survey, conducted in October 2021 among Italian lipid clinics included in the LIPIGEN Paediatric Group, was to investigate the current clinical approach in the management and treatment of paediatric patients with suspected FH. A digital questionnaire composed of 20 questions investigating nutritional treatment and nutraceutical and pharmacological therapy for children and adolescents with FH was proposed to the principal investigators of 30 LIPIGEN centres. Twenty-four centres responded to the section referring to children aged < 10 years and 30 to that referring to adolescents. Overall, 66.7% of children and 73.3% of adolescents were given lipid-lowering nutritional treatment as the first intervention level for at least 3-4 months (29.2% and 23.3%) or 6-12 months (58.3% and 53.3%). Nutraceuticals were considered in 41.7% (regarding children) and 50.0% (regarding adolescents) of the centres as a supplementary approach to diet. Lipid-lowering drug therapy initiation was mainly recommended (91.7% and 80.0%). In 83.3% of children and 96.7% of adolescents, statins were the most frequently prescribed drug. We highlighted several differences in the treatment of paediatric patients with suspected FH among Italian centres; however, the overall approach is in line with the European Atherosclerosis Society (EAS) recommendations for FH children and adolescents. We consider this survey as a starting point to reinforce collaboration between LIPIGEN centres and to elaborate in the near future a consensus document on the management of paediatric patients with suspected FH so as to improve and uniform detection, management, and treatment of these patients in our country.